• Strong commercial performance with 55% year-over-year revenue growth in FY2024
• Advancing multiple late-stage therapeutic assets to pivotal trials in 2025
• Preparing for multi-product launches in the US, including Zircaix, Gozellix and Pixclara

Telix Pharmaceuticals presented its outlook for 2025 at the JP Morgan Healthcare Conference, showcasing the company's unique position as a leading pure-play radiopharmaceutical company. The key highlights included strong commercial performance, with unaudited FY2024 revenue reaching US$517 million, a 55% increase year-over-year. Telix is advancing a deep theranostic pipeline, with plans to target three assets in pivotal trials in 2025, focusing on urology, neuro-oncology, and musculoskeletal oncology. The company is preparing for multi-product launches in the US market, including Zircaix for kidney cancer imaging, Gozellix for prostate cancer imaging, and Pixclara for glioma imaging. Telix also discussed its late-stage therapeutic pipeline, including TLX591 for prostate cancer, TLX250 for renal cell carcinoma, and TLX101 for glioblastoma, as well as its early-stage pipeline of 'next-generation' radiopharmaceuticals. The presentation highlighted Telix's strong commercial record, deep pipeline, and manufacturing capabilities as key drivers of the company's growth and ability to meet global demand for its products.

Telix provided unaudited FY2024 revenue of US$517 million, a 55% increase from FY2023. The company's full-year FY2024 revenue guidance was US$490 million to US$510 million.

Telix outlined a clear strategy for 2025, focusing on advancing multiple late-stage therapeutic assets to pivotal trials, preparing for multi-product launches in the US market, and further expanding its global commercial footprint. The company also discussed its plans to harness the potential of alpha-emitting isotopes and further develop its in-house discovery platform for 'next-generation' radiopharmaceuticals.